Inhibrx Biosciences INBX
NASDAQ INBX
$90.25 -1.49 (-1.62%)
As of: Nov 10, 2026 · 3:08 PM EST

Inhibrx Biosciences (INBX) Operating Leases (2023 - 2026)

Updated

Analysis

Inhibrx Biosciences (INBX) Operating Leases (2023 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn
10 Inhibrx Biosciences 1.45 Bn 882.42 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 2.85 Mn
Dec 31, 2025 4.13 Mn
Sep 30, 2025 4.74 Mn
Jun 30, 2025 5.34 Mn
Mar 31, 2025 5.90 Mn
Dec 31, 2024 6.45 Mn
Dec 31, 2023 1.11 Mn
API Access

Inhibrx Biosciences Operating Leases API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=operating-leases&ticker=INBX&period=max&api_key=YOUR_API_KEY